ESGAB breakpoint determination: temafloxacin.
作者信息
Phillips I, Acar J, Baquero F, Bergan T, Forsgren A, Wiedemann B
出版信息
Eur J Clin Microbiol Infect Dis. 1991 Nov;10(11):991-2. doi: 10.1007/BF02005465.
PMID:1665417
Abstract
摘要
相似文献
1
ESGAB breakpoint determination: temafloxacin.ESGAB断点确定：替马沙星。
Eur J Clin Microbiol Infect Dis. 1991 Nov;10(11):991-2. doi: 10.1007/BF02005465.
2
Breakpoint determination: rufloxacin.断点确定：鲁氟沙星。
Eur J Clin Microbiol Infect Dis. 1993 Jul;12(7):574-5. doi: 10.1007/BF01970973.
3
NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients.
Drugs. 1995;49 Suppl 2:326-30. doi: 10.2165/00003495-199500492-00087.
4
Susceptibility of recent clinical isolates to temafloxacin (A-63004) and other antimicrobial agents.近期临床分离株对替马沙星（A-63004）及其他抗菌药物的敏感性。
Drugs Exp Clin Res. 1992;18(8):311-7.
5
In vitro activity of temafloxacin against gram-negative bacteria: an overview.替马沙星对革兰氏阴性菌的体外活性：综述
Am J Med. 1991 Dec 30;91(6A):19S-23S. doi: 10.1016/0002-9343(91)90304-g.
6
Pharmacokinetics of marbofloxacin in horses.马波沙星在马体内的药代动力学
Equine Vet J. 2002 Jul;34(4):366-72. doi: 10.2746/042516402776249191.
7
Sparfloxacin and other new fluoroquinolones.司帕沙星及其他新型氟喹诺酮类药物。
J Antimicrob Chemother. 1992 Dec;30(6):739-44. doi: 10.1093/jac/30.6.739.
8
Activity of temafloxacin and other fluoroquinolones against typical and atypical community-acquired respiratory tract pathogens.替马沙星及其他氟喹诺酮类药物对典型和非典型社区获得性呼吸道病原体的活性。
Am J Med. 1991 Dec 30;91(6A):12S-14S. doi: 10.1016/0002-9343(91)90302-e.
9
Emergence of resistance to fluoroquinolones among bacteria causing infections in food animals in Denmark.
Vet Rec. 2000 Jan 15;146(3):76-8. doi: 10.1136/vr.146.3.76.
10
Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials.
Clin Pharm. 1992 Sep;11(9):753-66.
Zotero 插件